Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2022, Vol. 27 ›› Issue (10): 1182-1189.doi: 10.12092/j.issn.1009-2501.2022.10.013

Previous Articles     Next Articles

Reseach progress on the role of ErbB2 in cardiac disease

CHEN Yunjie 1,2, ZHOU Xuan 1, ZHANG Yuanbin 1, WANG Xu 2, LIN Zhu 1, ZHU Suyan 1   

  1. 1 Department of Pharmacy, Ningbo First Hospital, Ningbo 315010, Zhejiang, China; 2 School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China
  • Received:2022-07-29 Revised:2022-08-22 Online:2022-10-27 Published:2022-11-14

Abstract: Cardiac disease is the general term of diseases, caused by damage to the structure or abnormal function of the heart. Its morbidity and mortality have remained high, seriously threatening the lives and health of people. The tyrosine kinase receptor ErbB2 (also known as EGFR2 or HER2) was originally discovered for its oncogenic activity, however, recent studies have found that ErbB2 have protective effects in various heart diseases. Therefore, this article reviews the role and underlying mechanism of ErbB2 in myocardial infarction, myocardial ischemia/reperfusion injury, cardiac hypertrophy, heart failure, doxorubicin-induced cardiotoxic injury and diabetic cardiomyopathy. Furthermore, this article also preliminarily discusses the application prospects, limitations and development directions of ErbB2 as a clinical diagnostic marker and therapeutic target for heart disease. 

Key words: ErbB2, cardiac disease, diagnostic marker, therapeutic target

CLC Number: